Startups
Curemark is a pioneering, research-driven biotechnology company that develops and markets innovative products to fulfill needs in neurological medicine. The company is committed to improving the quality of life for children and adults with neurological disorders by providing safe, effective and clinically proven solutions. The company’s flagship product is focused on treating children with autism. Curemark’s breakthrough product is based on proprietary technology developed by the company’s CEO and founder, Dr. Joan Fallon.
Overview
Location
United States, New York, Rye
Employees
11-50
Phone
+1 914-824-9700
Total raised
$38.5M
Founded date
2006
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Oct 8, 2013 | Funding round | $18.5M |
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 21, 2014 | California payer one of 9 healthcare companies on RedHerring Top 100 list | Last year the company did a study of 120,000 employees enrolled in its program over a 3-year period. SeeChange reported these results: Close to 80% of the incentive program members earned points, with slightly increased and sustained engage... |
| Oct 8, 2013 | CureMark’s drug uses digestive system to treat autism, raises $18.5M in runup to NDA submission | CM-AT was designated as a Fast Track drug in 2010 by the FDA. Drugs that qualify for that classification are for the treatment of serious conditions that fill an unmet medical need. It expedites the review process. CureMark claims its drug ... |
| Oct 8, 2013 | Curemark Closes $18.5M Equity Financing | Curemark LLC, a Rye, NY-based drug research and development company, closed an $18.5m in equity financing. The round was led by a European institutional investor. The company intends to use the funds for the completion and filing requiremen... |
| CureMark’s drug uses digestive system to treat autism, raises $18.5M in runup to NDA submission | The causes of autism and how prevalent it really is have been the stuff of impassioned debate and controversy. It has stirred a variety of opinions from its definition to diagnosis tools to the best treatment approach. A biotechnology compa... | |
| California payer one of 9 healthcare companies on RedHerring Top 100 list | SeeChange Health has won a Red Herring Top 100 North America Award. The award recognizes private companies from North America for innovation and new technology in their respective industries. SeeChange Health offers Health Insurance and Hea... |
Reviews 0
FAQ about Curemark, LLC
When was Curemark, LLC founded?
Curemark, LLC was founded in 2006.
How much funding has Curemark, LLC raised?
Curemark, LLC has raised $38.5M in total across 2 funding rounds.
What funding rounds has Curemark, LLC raised?
Parsers VC lists 2 funding rounds of Curemark, LLC, among them a funding round of $18.5M on Oct 8, 2013.
What has the press written about Curemark, LLC?
Parsers VC has collected 6 articles mentioning Curemark, LLC, among them “California payer one of 9 healthcare companies on RedHerring Top 100 list” (May 21, 2014) and “CureMark’s drug uses digestive system to treat autism, raises $18.5M in runup to NDA submission” (Oct 8, 2013).
Is Curemark, LLC still active?
Yes, Curemark, LLC is active; its latest activity on Parsers VC dates from Jul 13, 2015.